RHEUMATOID ARTHRITIS ( RA ) is an important cause ofmorbidity and mortality in the United Kingdom. It is characterised by chronic inflammatory infiltration ?f sy?ovium and o~her connective tissues, with resulting impairment ofphysical, psychological and social function. Control of inflammation, therefore, is central to its manag.e~en~,,:ithin the wider context of patient care by a multi-disciplinary team of health-care professionals. At present there is no ideal drug therapy for RA. Nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs) ["second! third line" drugs] require a balance of efficacy with toxicity which limits their usefulness for a significant number of patients.
,!,he rheuma!olo~ical 'Holy Grail' remains the pursuit of disease-specific mtervention. Although much is now under~to~d about t~e molecular events surrounding synovial inflammation and cartilage destruction no aetiological agent has yet been identified. Biological therapies, particularly directed against T-lymphocytes and modification of cytokine activities (eg. tumour necrosis factor a), are emerging, but as yet, appear no more specific than already available drugs. Why use DMARDs at all? The reduction in pain score morning~tiffne~s, ES.R and C-reactive protein is highl; reproducible as ISthe Improved function achieved during response to therapy. I Over a longer period, DMARDs may also slow the rate ofradiological progression ofbone erosions.' It is true that few patients achieve the American Rheumatism Association criteria for disease remission 3 but a greater than 50% improvement in the above indices will have a significant impact on quality of life. We currently offer DMARD therapy to patients with active synovitis, radiological evidence of bone erosion or rapid functional decline and similar criteria are applied regardless of gender, disease duration or age. ydroxychloroquine,sulphasalazine, D-penicillamine or mtramuscular gold are often chosen first, after which methotrexate or azathioprine may also be used. Prednisolone is not used routinely because of associated long-term morbidity. Moreover, it has never been proven to posse.ss tru~".second line" properties, although studies addressmg this Issue are proceeding.
Aft~r one year approximately two thirds ofpatients will remam on sulphasalazine, penicillamine or intramuscular gold and around one third after five years.' Adverse effects remain a major cause of drug cessation. Manoeuvres designed to reduce toxicity, such as sulphasalazine desensitisation" or folic acid!methotrexate combination therapY; areyrobably beneficial but significant problems remam, particularly the prediction ofpatient susceptibility to adverse effects. Concern about drug toxicity should, however,. be balanced b~recollection of RA mortality rates, which for some patient groups compare with those ofHodgkin's lymphoma or triple-vessel cardiac disease.'
Despite DMARD therapy, the prognosis remains poor for a number of RA patients, particularly those who are seropositive, erosive and have early impairment of functional status," and alternative approaches for DMARD use have been proposed. Magnetic resonance images ofRAjoints demonstrate erosive changes as early as three months after symptomatic onset.v'? Thus, there might b~considerable advantage in treating patients aggressively as soon after diagnosis as possible. yn~ortunately, we l~ck useful and reliable prognostic indicators, and there IS concern that patients destined for a benign course will receive potentially toxic therapy. Should treatment initially be with combinations ofdrugs such as corticosteroids and cytotoxic agents, normally reserved for advanced disease, and then be scaled down to a single recognised" second line" drug for maintenance therapy? In a manner analogous to the management of haematological malignancy, the eradication of the inflammatory response would become the therapeutic goal. Chemotherapeutic regimes may be devised to induce remission of RA, and subsequent flares then be treated as disease recurrence with modified versions of the inducti~e pr?tocol. Currently, such schemes could only be practised m the confines ofclinical trials and in patients in who~so~e prognostic features were suggestive of aggressrve disease, ego HLA DR4+, or early erosions. Th~limiting factor remains the inherent toxicity of such regnnens. Nevertheless, in our routine practice, patients are being offered DMARDs earlier in the course of their disease and studies are underway to assess the impact of this strate~. The corollary t~this is the requirement for early referral to rheumatologists from the community -the differentiation ofreactive arthritis and osteoarthritis from inflammatory polyarthritis ·which will progress to des~l1!ctive disease is a vital precondition to therapeutic decisions, Furthermore, early connective tissue disease such as SLE, scleroderma or vasculitis is not always as easy to diagnose in the initial stages as the textbooks might suggest. Most RA patients are still receiving an NSAID for symptomatic relief. While they do reduce pain and stiffness, NSAID do not alter disease progression. Recently, there has been increased recognition of their associated morbidity and mortality, which may be comparab~e to~at ofsome DMARDS, especially involving the gastromtestmal and renal systems.11.12,13 Indeed it may be preferable to achieve disease control with a DMARD and thereafter reduce or halt NSAID therapy. Coprescription of GI-protective agent with NSAIDs seems reasonable," however, the benefits of using triple therapy in patients with Helicobacter pylori, but who Comment continue with NSAIDs have not been evaluated -can we reasonably expect benefits to be sustained? The recent recognition ofisomers ofthe cyclo-oxygenase enzyme ( COXl and COX2 ) with different functional profiles may allow more selective anti-prostaglandin therapy with milder adverse effects, providing a safer adjunct to DMARD therapy in the future." Inflammatory disease activity, immobility, low body weight and in some instances, steroid therapy predispose RA patients to osteoporosis and the importance of providing prophylaxis has become evident." Moreover, there is evidence that hormone replacement therapy may provide symptomatic benefit in RA. 15 , 16 There may therefore be benefit in offering HRT or calcium replacement/bisphophonates to post menopausal RA patients, especially if previously or currently receiving corticosteroids. Formal study ofoutcome following such intervention is underway in several centres. The future oftherapy seems divided between meticulous use ofthe old, combined with innovative use ofthe new. Recently monoclonal antibodies again TNFa have been shown to provide benefit." Enthusiasm for such approaches should be tempered by caution, recalling that improvement is short-lived and the longer-term effects of blocking a pleiotropic cytokine are not yet clear. The development of metalloproteinase inhibitors and chondroprotective agents offer further hope that destructive disease might be delayed or prevented, but as yet are not available for extensive clinical trial. Successful therapy will depend on integration of novel agents in combination with, and complementary to, revised applications offamiliar drugs.
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